[Pressure and metabolic effects of terazosin in essential hypertension].
To assess the efficacy and safety of different doses of the alpha-1 blocker terazosin on long-term therapy, 12 essential hypertensives (7 males, 5 females, aged 27-61) were investigated. The study was conducted according to the Latin square design and each patient underwent 4 periods of treatment with 2, 5, 10 mg/day terazosin and placebo, in a double-blind, randomized order. Each treatment lasted 4 weeks. In comparison to placebo, a fall in diastolic pressure was observed already with the 2 mg/daily dose, with a decrease > 10 mmHg in 7 patients (responders). Body weight increased in a dose dependent manner, while atrial natriuretic peptide, serum glucose and insulin during oral glucose tolerance test, total cholesterol, HDL and LDL cholesterol, triglycerides were unaffected. It is concluded that terazosin is effective and safe in essential hypertensives already at 2 mg daily dose. Further reduction in blood pressure at higher doses is likely to be counteracted by salt and water retention.
Valle
R
R
Clinica Medica I, Università degli Studi, Padova.
Semplicini
A
A
Serena
L
L
Gebbin
A
A
Fontebasso
A
A
Gerardi
G
G
De Toni
R
R
Pessina
A C
AC
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D001786:Blood Glucose; D008055:Lipids; D009320:Atrial Natriuretic Factor; C041226:Terazosin; D011224:Prazosin
Effetti pressori e metabolici della terazosina nell'ipertensione essenziale.